NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company developing novel drugs and functional genomics solutions with a primary focus on cancer. The successful completion of the Human Genome Project signals a new age in medical discovery centered on protein research. The rapidly growing knowledge base of the human genome provides an unprecedented opportunity to launch a revolutionary paradigm for drug discovery based on protein analysis. NewLink remains steadfast in its primary focus to take novel treatments and diagnostics through the clinical trials process and bringing products to market. The company is currently conducting Phase I/II clinical trials with its proprietary HyperAcute® vaccine ( www.newlinkgenetics.com )